A 61-year-old man in California is lucky to be alive after a combination of herbal supplements he was taking for joint pain ended up utterly wrecking his body, landing him in intensive care and in a delirious state for months. His case is reported in the Annals of Internal Medicine: Clinical Cases .

The man turned up at a hospital in San Francisco in bad shape, but with nonspecific problems that had begun just two days earlier. His back hurt, he was feverish, nauseous, bloated, and he hadn’t been eating much. He was so weak he couldn’t walk or get out of bed without help. His heart rate and breathing rate were high. His blood pressure was low. There were multiple wounds on his lower body in various stages of healing.

Initial exams and lab work revealed Staphylococcus aureus bacteria in his blood. There was also an abscess on his shoulder and an infection in and around his spine, which was worsening. Doctors wanted to perform a surgical procedure to relieve the pressure building up on his spinal cord and nerves, but his blood pressure was too low—and then he went into hemorrhagic shock from bleeding in his gastrointestinal tract. Doctors transferred him to the intensive care unit.

Read full article

Comments

A 61-year-old man in California is lucky to be alive after a combination of herbal supplements he was taking for joint pain ended up utterly wrecking his body, landing him in intensive care and in a delirious state for months. His case is reported in the Annals of Internal Medicine: Clinical Cases .

The man turned up at a hospital in San Francisco in bad shape, but with nonspecific problems that had begun just two days earlier. His back hurt, he was feverish, nauseous, bloated, and he hadn’t been eating much. He was so weak he couldn’t walk or get out of bed without help. His heart rate and breathing rate were high. His blood pressure was low. There were multiple wounds on his lower body in various stages of healing.

Initial exams and lab work revealed Staphylococcus aureus bacteria in his blood. There was also an abscess on his shoulder and an infection in and around his spine, which was worsening. Doctors wanted to perform a surgical procedure to relieve the pressure building up on his spinal cord and nerves, but his blood pressure was too low—and then he went into hemorrhagic shock from bleeding in his gastrointestinal tract. Doctors transferred him to the intensive care unit.

Read full article

Comments

A 61-year-old man in California is lucky to be alive after a combination of herbal supplements he was taking for joint pain ended up utterly wrecking his body, landing him in intensive care and in a delirious state for months. His case is reported in the Annals of Internal Medicine: Clinical Cases .

The man turned up at a hospital in San Francisco in bad shape, but with nonspecific problems that had begun just two days earlier. His back hurt, he was feverish, nauseous, bloated, and he hadn’t been eating much. He was so weak he couldn’t walk or get out of bed without help. His heart rate and breathing rate were high. His blood pressure was low. There were multiple wounds on his lower body in various stages of healing.

Initial exams and lab work revealed Staphylococcus aureus bacteria in his blood. There was also an abscess on his shoulder and an infection in and around his spine, which was worsening. Doctors wanted to perform a surgical procedure to relieve the pressure building up on his spinal cord and nerves, but his blood pressure was too low—and then he went into hemorrhagic shock from bleeding in his gastrointestinal tract. Doctors transferred him to the intensive care unit.

Read full article

Comments

One of the things that emerging diseases, including the COVID and Zika pandemics, have taught us is that it’s tough to keep up with infectious diseases in the modern world. Things like air travel can allow a virus to spread faster than our ability to develop therapies. But that doesn’t mean biotech has stood still; companies have been developing technologies that could allow us to rapidly respond to future threats.

There are a lot of ideas out there. But this week saw some early clinical trial results of one technique that could be useful for a range of infectious diseases. We’ll go over the results as a way to illustrate the sort of thinking that’s going on, along with the technologies we have available to pursue the resulting ideas.

The best antibodies

Any emerging disease leaves a mass of antibodies in its wake—those made by people in response to infections and vaccines, those made by lab animals we use to study the infectious agent, and so on. Some of these only have a weak affinity for the disease-causing agent, but some of them turn out to be what are called “broadly neutralizing.” These stick with high affinity not only to the original pathogen, but most or all of its variants, and possibly some related viruses.

Read full article

Comments

One of the things that emerging diseases, including the COVID and Zika pandemics, have taught us is that it’s tough to keep up with infectious diseases in the modern world. Things like air travel can allow a virus to spread faster than our ability to develop therapies. But that doesn’t mean biotech has stood still; companies have been developing technologies that could allow us to rapidly respond to future threats.

There are a lot of ideas out there. But this week saw some early clinical trial results of one technique that could be useful for a range of infectious diseases. We’ll go over the results as a way to illustrate the sort of thinking that’s going on, along with the technologies we have available to pursue the resulting ideas.

The best antibodies

Any emerging disease leaves a mass of antibodies in its wake—those made by people in response to infections and vaccines, those made by lab animals we use to study the infectious agent, and so on. Some of these only have a weak affinity for the disease-causing agent, but some of them turn out to be what are called “broadly neutralizing.” These stick with high affinity not only to the original pathogen, but most or all of its variants, and possibly some related viruses.

Read full article

Comments

One of the things that emerging diseases, including the COVID and Zika pandemics, have taught us is that it’s tough to keep up with infectious diseases in the modern world. Things like air travel can allow a virus to spread faster than our ability to develop therapies. But that doesn’t mean biotech has stood still; companies have been developing technologies that could allow us to rapidly respond to future threats.

There are a lot of ideas out there. But this week saw some early clinical trial results of one technique that could be useful for a range of infectious diseases. We’ll go over the results as a way to illustrate the sort of thinking that’s going on, along with the technologies we have available to pursue the resulting ideas.

The best antibodies

Any emerging disease leaves a mass of antibodies in its wake—those made by people in response to infections and vaccines, those made by lab animals we use to study the infectious agent, and so on. Some of these only have a weak affinity for the disease-causing agent, but some of them turn out to be what are called “broadly neutralizing.” These stick with high affinity not only to the original pathogen, but most or all of its variants, and possibly some related viruses.

Read full article

Comments

Digital reading devices like the Kindle have existed for almost 20 years, and the standard eReader form factor has hardly changed at all. Amazon, Boox, and a few other companies have offered larger E Ink screens, but how about something smaller? Boox has unveiled its second-generation Palma e-reader, which still fits in your pocket but adds a color screen and mobile data connectivity.

The first-gen Palma launched last year, earning fans who saw it as a way to read and access some apps without the full spate of distracting smartphone experiences. Boox e-readers are essentially Android tablets with E Ink screens and a few software quirks that arise from their unofficial Google Play implementation. The second-gen Palma might offer more opportunities for distraction because it’s almost a smartphone.

The Palma 2 Pro upgrades the 6.1-inch monochrome display from the original to a 6.13-inch color E Ink Kaleido display. That’s the same technology used in Amazon’s Kindle Colorsoft . The Amazon reader is a bit larger with its 7-inch display and chunkier bezels. Of course, the Kindle isn’t trying to fit in your pocket like the Palma 2 Pro, which is roughly the size and shape of a phone.

Read full article

Comments

Digital reading devices like the Kindle have existed for almost 20 years, and the standard eReader form factor has hardly changed at all. Amazon, Boox, and a few other companies have offered larger E Ink screens, but how about something smaller? Boox has unveiled its second-generation Palma e-reader, which still fits in your pocket but adds a color screen and mobile data connectivity.

The first-gen Palma launched last year, earning fans who saw it as a way to read and access some apps without the full spate of distracting smartphone experiences. Boox e-readers are essentially Android tablets with E Ink screens and a few software quirks that arise from their unofficial Google Play implementation. The second-gen Palma might offer more opportunities for distraction because it’s almost a smartphone.

The Palma 2 Pro upgrades the 6.1-inch monochrome display from the original to a 6.13-inch color E Ink Kaleido display. That’s the same technology used in Amazon’s Kindle Colorsoft . The Amazon reader is a bit larger with its 7-inch display and chunkier bezels. Of course, the Kindle isn’t trying to fit in your pocket like the Palma 2 Pro, which is roughly the size and shape of a phone.

Read full article

Comments

Digital reading devices like the Kindle have existed for almost 20 years, and the standard eReader form factor has hardly changed at all. Amazon, Boox, and a few other companies have offered larger E Ink screens, but how about something smaller? Boox has unveiled its second-generation Palma e-reader, which still fits in your pocket but adds a color screen and mobile data connectivity.

The first-gen Palma launched last year, earning fans who saw it as a way to read and access some apps without the full spate of distracting smartphone experiences. Boox e-readers are essentially Android tablets with E Ink screens and a few software quirks that arise from their unofficial Google Play implementation. The second-gen Palma might offer more opportunities for distraction because it’s almost a smartphone.

The Palma 2 Pro upgrades the 6.1-inch monochrome display from the original to a 6.13-inch color E Ink Kaleido display. That’s the same technology used in Amazon’s Kindle Colorsoft . The Amazon reader is a bit larger with its 7-inch display and chunkier bezels. Of course, the Kindle isn’t trying to fit in your pocket like the Palma 2 Pro, which is roughly the size and shape of a phone.

Read full article

Comments